Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled trial of MK-6194 in adults with systemic lupus erythematosus
CTR20240947Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of PT101 in systemic lupus erythematosus (SLE), sponsored by Merck & Co.. Started Mar 2024; status: terminated.
02
Drugs
PT101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20240947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240947.